Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07300059

Short-Term Glycemic Effects of Liquid Metformin vs Standard Tablets

Short-Term Glycemic Effects of Two Concentrations of Liquid Metformin Versus Standard Metformin Tablets in Healthy Adults

Status
Not Yet Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
24 (estimated)
Sponsor
Aspargo Labs, Inc · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This is an open-label, randomized study evaluating the short-term glycemic effects of two concentrations of liquid metformin formulations (100 mg/mL and 250 mg/mL) compared with standard immediate-release metformin tablets in healthy adult subjects. Participants will receive single or short-term doses of study treatments in a randomized sequence. Blood glucose measurements and other glycemic indicators will be collected to assess short-term pharmacodynamic effects. Safety and tolerability will also be monitored.

Conditions

Interventions

TypeNameDescription
DRUGLiquid Metformin 100 mg/mLA single oral dose of a liquid metformin formulation at a concentration of 100 mg/mL will be administered under fasting conditions in one period of the crossover to assess short-term glycemic effects and safety.
DRUGLiquid Metformin 250 mg/mLA single oral dose of a liquid metformin formulation at a concentration of 250 mg/mL will be administered under fasting conditions in one period of the crossover to assess short-term glycemic effects and safety.
DRUGStandard Metformin Immediate-Release TabletA single oral dose of standard metformin immediate-release tablet(s) will be administered under fasting conditions in one period of the crossover to assess short-term glycemic effects and safety.

Timeline

Start date
2026-07-15
Primary completion
2026-08-15
Completion
2026-08-28
First posted
2025-12-23
Last updated
2025-12-23

Regulatory

Source: ClinicalTrials.gov record NCT07300059. Inclusion in this directory is not an endorsement.